Join
Live feed
·
PRReleasevia Quantisnow
Janux Therapeutics Inc. logo

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

ByQuantisnow·Wall Street's wire, on your screen.
JANX· Janux Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JANX (Janux Therapeutics Inc.) and more on Quantisnow.